Supernus Pharmaceuticals (SUPN) reported $719M in revenue for fiscal 2025, +8.6% year on year. That ranks #1995 by revenue among 2853 SEC filers and #190 in Healthcare. It posted a net loss of −$38.6M for the same year. Revenue has grown 62.5% a year on average since 2011 ($803,000 then). The fiscal 2025 balance sheet shows $1.5B in total assets, $128M in cash and $379M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $719M | +8.6% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$62.3M | −$144M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$38.6M | −$113M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $47.3M | −72.5% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $1.3M | +84.6% | FY20252025-12-31 |
| Total assetsAssets | $1.5B | +6.2% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $1.1B | +2.5% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $128M | +85.3% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $379M | +1,532.9% | FY20212021-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $208M | −$2.3M | Open → |
| Q2 20262026-06-30 | $219M | −$58.4M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Supernus Pharmaceuticals, Inc.
- Ticker
- SUPN
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001356576
Filings
- 10-QAug 3, 2026Open filing →
- 10-QMay 5, 2026Open filing →
- 10-KMar 2, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| RepligenRGEN | $738M | $48.9M |
| Pacira BiosciencesPCRX | $726M | $7.0M |
| Amphastar PharmaceuticalsAMPH | $720M | $98.1M |
| Supernus PharmaceuticalsSUPN | $719M | −$38.6M |
| Avanos MedicalAVNS | $701M | −$72.9M |
| Kiniksa Pharmaceuticals InternationalKNSA | $678M | $59.0M |
| SNDLSNDL | $677M | −$11.3M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Supernus Pharmaceuticals — Key figures |url=https://companiesranked.com/en/company/supernus-pharmaceuticals |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Supernus Pharmaceuticals — Key figures. CompaniesRanked. https://companiesranked.com/en/company/supernus-pharmaceuticalsBibTeX
@misc{companiesranked-en-company-supernus-pharmaceuticals-2026,
author = {{CompaniesRanked}},
title = {{Supernus Pharmaceuticals — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/supernus-pharmaceuticals}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001356576-26-000011 · March 2, 2026
{{cite web |title=Supernus Pharmaceuticals — Key figures — 10-K (0001356576-26-000011) |url=https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-02}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.